GlassScriptPhysician profile
Michelle Smith
NPI 1194477588
$1,048.60
in general payments reported to CMS, 2019-2025
17 companies · $186 in 2025
The $186 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $224 · 2023: $460 · 2024: $179 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $824.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $332.20 | 2022-2025 | |
| Novo Nordisk INC | $152.91 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $108.72 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $88.04 | 2022-2023 | |
| Lilly USA, LLC | $66.50 | 2022-2025 | Zepbound, Mounjaro, Emgality |
| Sanofi Pasteur INC. | $55.57 | 2022-2024 | |
| Exact Sciences Corporation | $40.12 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $37.83 | 2023 | Rexulti |
| Pfizer INC. | $28.99 | 2024-2025 | |
| Organon LLC | $24.89 | 2022-2025 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $20.37 | 2023 | |
| Amgen INC. | $18.97 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.41 | 2023 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $15.20 | 2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $14.55 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $14.39 | 2023 | Accrufer |
| Amneal Pharmaceuticals LLC | $13.94 | 2023 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.